Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,281.0
3.0 (0.09%)

 

  • STI Straits Times Index
    3,281.0
    3.0 (0.09%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,595.8
    7.9 (0.50%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    29,056.4
    173.4 (0.60%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,075.5
    1.4 (0.05%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    24,041.3
    108.1 (0.45%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,291.7
    5.6 (0.09%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,250.6
    2.5 (0.11%)
    Index delayed 20 minutes
  • XAO XAO
    7,180.3
    21.7 (0.30%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,723.5M
  • Value: 1,021.1M
  • Rise: 204
  • Fall: 116
  • Unch: 499

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
AsiaPhos0.047+0.019
Golden Agri-Res0.235-
OEL0.029+0.009
Sincap0.013+0.003
Rex Intl0.192+0.011
AusGroup^0.048+0.001
BlackGoldNatural0.018+0.002
AsiaMedic0.013+0.002
Ley Choon0.022+0.004
GCCP0.009+0.002

World Indices

World Indices
Name Last Change
Nasdaq 9,388.9 +31.8
HSI 29,056.4 +173.4
HSCEI 11,419.9 +91.5
Jakarta 6,291.7 +5.6
Nikkei 225 24,041.3 +108.1
SSE Comp 3,075.5 +1.4
Shanghai A 3,222.5 +1.4
Shanghai B 260.1 +2.0
PSE Comp 0.0
KOSPI 2,250.6 +2.5

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

NOVABAY PHARMACEUTICALS INC NOVABAY PHARMACEUTICALS INC
Updated on 17 Jan 2020 (End of trading day)
Last (USD): 0.628 Change: +0.008 High: 0.640 Remarks: -
Change (%): +1.26 Low: 0.610
Open 0.640 Yesterday's Close 0.6203
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 223,906 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -0.42753 Trailing EPS (USD) e -0.54014 NAV (USD) b 0.1909
PE a - Trailing PE f - Price / NAV b 3.2902
Dividend (USD) d - Cash In Hand (USD) g 0.5892 Issued & Paid-up Shares c 27,902,000
Dividend Yield (%) d - Price / Cash In Hand g 1.066 Treasury Shares h -
Beta - 75 Daysi 0.736 R-Squared - 75 Days(%)i 0.73 Market Cap (M) 9.616
Beta - 500 Daysi 0.710 R-Squared - 500 Days (%)i 0.02 Enterprise Value (M) 5.910
Piotroski F Score 4 Exchange Code NBY Par Value ( $ ) n.a.
52 Weeks Volatility (%) 223.55 Free Float (%) 58.2
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 28 Oct 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 13 Jul 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference NOVABAY PHARMACEUTICALS INC NYSE American 9.616 - - 3.2902 -
Industry Biotechnology NYSE American 87.230 - - 3.3148 -
Local Peer PFENEX INC NYSE American 289.407 - - 5.1833 -
Local Peer NAVIDEA BIOPHARMACEUTICALS INC NYSE American 235.200 - - -308.5106 -
Local Peer NANOVIRICIDES INC NYSE American 211.922 - - 23.2205 -
Local Peer MATINAS BIOPHARMA HOLDINGS INC NYSE American 137.038 - - 4.0358 -
Local Peer LINEAGE CELL THERAPEUTICS INC NYSE American 121.138 - - 1.0340 -
Local Peer 22ND CENTURY GROUP INC NYSE American 117.146 - - 2.1182 -
Local Peer PALATIN TECHNOLOGIES INC NYSE American 108.505 3.033 2.936 1.1288 -
Local Peer CEL-SCI CORP NYSE American 93.640 - - 18.2397 -
Local Peer SYNTHETIC BIOLOGICS INC NYSE American 65.406 - - 637.5000 -
Local Peer ISORAY INC NYSE American 48.415 - - 6.9620 -
Local Peer ARMATA PHARMACEUTICALS INC NYSE American 27.884 - - 1.5378 -
Local Peer ORAGENICS INC NYSE American 22.770 - - 1.5918 -
Other Local Peers INDIA GLOBALIZATION CAPITAL INC (NYSE American), IBIO INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), AIM IMMUNOTECH INC (NYSE American)
Global Peer AMGEN INC NASDAQ 143,489.494 17.094 17.787 13.1317 2.317
Global Peer CSL ASX 136,206.687 50.768 50.768 18.2018 0.884
Global Peer GILEAD SCIENCES INC NASDAQ 79,679.147 14.607 29.588 3.8672 3.668
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 60,643.685 28.928 28.288 11.5437 -
Global Peer BIOGEN INC NASDAQ 51,516.191 11.627 9.548 3.6808 -
Global Peer ILLUMINA INC NASDAQ 47,733.840 57.789 49.058 10.7533 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 42,374.657 17.335 19.762 4.0340 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 27,953.692 88.461 26.101 5.8875 0.678
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 25,065.632 323.010 17.048 2.4178 -
Other Global Peers SINO BIOPHARM (HKEx), SEATTLE GENETICS INC (NASDAQ), WUXI BIO (HKEx), INCYTE CORPORATION (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), BEIGENE (HKEx), EXACT SCIENCES CORP (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), MODERNA INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), REPLIGEN CORP (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), GENSCRIPT BIO (HKEx), Lonza (SGX), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), FIBROGEN INC (NASDAQ), 3SBIO (HKEx), CRISPR THERAPEUTICS AG (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), NATERA INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), UNIQURE N.V. (NASDAQ), KODIAK SCIENCES INC (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), VIELA BIO INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), EPIZYME INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), SYNTHORX INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), XENCOR INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), ARVINAS INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), REGENXBIO INC (NASDAQ), HAOHAI BIOTEC (HKEx), INTRA-CELLUAR THERAPIES INC (NASDAQ), ALPHAMAB-B (HKEx), CORTEXYME INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VERACYTE INC (NASDAQ), NEXTCURE INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), TG THERAPEUTICS INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), ALECTOR INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), NGM BIOPHARMACEUTICALS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), FRONTAGE (HKEx), KARYOPHARM THERAPEUTICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), POLYNOVO LIMITED (ASX), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), AVITA MEDICAL LTD (ASX), CKLIFE SCIENCES (HKEx), LUMINEX CORP(DEL) (NASDAQ), OPKO HEALTH INC (NASDAQ), XBIOTECH INC (NASDAQ), DERMIRA INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), INTREXON CORP (NASDAQ), VIVA BIOTECH (HKEx), AKEBIA THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), MESOBLAST LTD (ASX), ACHILLION PHARMACEUTICALS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), OMEROS CORP (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), CYTOKINETICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ASCENTAGE-B (HKEx), SORRENTO THERAPEUTICS INC (NASDAQ), NANTKWEST INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), IMMUNOGEN INC (NASDAQ), RETROPHIN INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), KADMON HLDGS INC (NYSE), REPLIMUNE GROUP INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), AVROBIO INC (NASDAQ), ARDELYX INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), MACROGENICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), SINOMAB BIO-B (HKEx), VOYAGER THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), AGENUS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), MERUS B V (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), BELLUS HEALTH INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ESSEX BIO-TECH (HKEx), ASCLETIS-B (HKEx), ANAPTYSBIO INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PERSONALIS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), COMPUGEN (NASDAQ), PDL BIOPHARMA INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), RECRO PHARMA INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), LEE'S PHARM (HKEx), PUMA BIOTECHNOLOGY INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), IVERIC BIO INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), VBI VACCINES INC CDA (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), MEDICINOVA INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), GERON CORP (NASDAQ), NEXT SCIENCE LTD (ASX), WAVE LIFE SCIENCES LTD (NASDAQ), DPHARMA (Bursa), ADMA BIOLOGICS INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), KAMADA (NASDAQ), TELIX PHARMACEUTIC (ASX), LIMINAL BIOSCIENCES INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), BBI LIFE SCI (HKEx), CHIASMA INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), XOMA CORP (NASDAQ), IMV INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), ATHERSYS INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), ARAVIVE INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), MONOPAR THERAPEUTICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), CONTRAFECT CORP (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), SAVARA INC (NASDAQ), NOVAVAX INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), VERASTEM INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), RESAPP HEALTH LIMITED (ASX), CYMABAY THERAPEUTICS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), ENZO BIOCHEM INC (NYSE), PYC THERAPEUTICS LIMITED (ASX), CHIMERIX INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), UNI-BIO GROUP (HKEx), CIDARA THERAPEUTICS INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), IMUGENE LIMITED (ASX), OTONOMY INC (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), ADURO BIOTECH INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), SESEN BIO INC (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), SYNLOGIC INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), INFLARX N V (NASDAQ), COHBAR INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), CATALYST BIOSCIENCES INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), TREVENA INC (NASDAQ), IMMUTEP LTD (ASX), ORGENESIS INC (NASDAQ), VERMILLION INC (NASDAQ), EQUILLIUM INC (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), VACCINEX INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), ORTHOCELL LIMITED (ASX), KEZAR LIFE SCIENCES INC (NASDAQ), ADVAXIS INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), INMUNE BIO INC (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), RESTORBIO INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), CT ENTERPRISE (HKEx), VASCULAR BIOGENICS LTD (NASDAQ), ZAFGEN INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), EVOGENE LTD (NASDAQ), SOLIGENIX INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), BIOSINO BIO-TEC (HKEx), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), OCUGEN INC (NASDAQ), BIOCARDIA INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), ANTEOTECH LIMITED (ASX), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), APTEVO THERAPEUTICS INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), BIOTRON (ASX), UNUM THERAPEUTICS INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), BIONOMICS LTD (ASX), MEMPHASYS LTD (ASX), GENETIC TECHNOLOGIES (ASX), REGENT PACIFIC (HKEx), ATYR PHARMA INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), TALI DIGITAL LIMITED (ASX), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), RHINOMED LIMITED (ASX), BIO-PATH HOLDINGS INC (NASDAQ), EXTRAWELL PHAR (HKEx), AETERNA ZENTARIS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), CCP TECHNOLOGIES LTD (ASX), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), VAXART INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), CELLMID LIMITED (ASX), SENESTECH INC (NASDAQ), IMMURON LIMITED (ASX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), PRECIPIO INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), PATRYS LIMITED (ASX), REGENEUS LTD (ASX), BIOCEPT INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), CONATUS PHARMACEUTICALS INC (NASDAQ), TOCAGEN INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED (ASX), ACHIEVE LIFE SCIENCE INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), ADALTA LTD (ASX), HEAT BIOLOGICS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), TROVAGENE INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), SIENNA CANCER DIAGNOSTICS LTD (ASX), CLEVELAND BIOLABS INC (NASDAQ), OPGEN INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), BENITEC BIOPHARMA LTD (ASX), BIOXYNE LIMITED (ASX), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), HAO WEN HLDGS (HKEx), MEDIBIO LIMITED (ASX), LIVING CELL TECHNOLOGIES (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SPHERIX INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), QT Vascular (SGX), MGRC (Bursa), SENECA BIOPHARMA INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), TBG DIAGNOSTICS LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), NANOLLOSE LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), BPH ENERGY LIMITED (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.008
+1.31 %
10 Days --0.003
-0.46 %
20 Days -+0.025
+4.16 %
Medium Term Return 3 Months -+0.013
+2.13 %
6 Months --0.522
-45.38 %
1 Year --0.502
-44.42 %
Long Term Return 2 Years --3.147
-83.36 %
3 Years --3.022
-82.79 %
5 Years --14.485
-95.84 %
Annualised Return Annualised --
-47.07 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.229 - 4.040 Change From 1 Year Low +0.399 % Change From 1 Year Low (%) +174.28
Change From 1 Year High -3.412 % Change From 1 Year High (%) -84.45
2 Years Range 0.229 - 4.040 Change From 2 Years Low +0.399 % Change From 2 Years Low (%) +174.28
Change From 2 Years High -3.412 % Change From 2 Years High (%) -84.45
5 Years Range 0.229 - 26.250 Change From 5 Years Low +0.399 % Change From 5 Years Low (%) +174.28
Change From 5 Years High -25.622 % Change From 5 Years High (%) -97.61
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. Its products include Avenova, NeutroPhase, and CelleRx. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.

Historical Price Data

Date Open High Low Close Volume VWAP
17 Jan 2020 0.640 0.640 0.610 0.628 223,906 -
16 Jan 2020 0.591 0.632 0.590 0.620 396,814 -
15 Jan 2020 0.593 0.620 0.571 0.590 331,369 -
14 Jan 2020 0.591 0.610 0.590 0.604 126,559 -
13 Jan 2020 0.620 0.630 0.581 0.600 156,679 -
10 Jan 2020 0.650 0.669 0.611 0.620 173,411 -
09 Jan 2020 0.640 0.660 0.620 0.650 228,320 -
08 Jan 2020 0.675 0.690 0.630 0.634 228,518 -
07 Jan 2020 0.621 0.700 0.621 0.671 616,336 -
06 Jan 2020 0.618 0.641 0.610 0.631 125,722 -
03 Jan 2020 0.621 0.660 0.621 0.631 134,213 -
02 Jan 2020 0.640 0.670 0.620 0.625 137,376 -
31 Dec 2019 0.630 0.679 0.620 0.640 181,684 -
30 Dec 2019 0.651 0.655 0.615 0.633 267,958 -
27 Dec 2019 0.663 0.687 0.624 0.657 460,696 -
26 Dec 2019 0.610 0.770 0.610 0.640 577,232 -
24 Dec 2019 0.617 0.629 0.610 0.620 74,415 -
23 Dec 2019 0.607 0.630 0.600 0.617 278,514 -
20 Dec 2019 0.586 0.605 0.586 0.603 186,755 -
19 Dec 2019 0.582 0.600 0.580 0.590 132,729 -
18 Dec 2019 0.580 0.603 0.570 0.592 194,263 -
17 Dec 2019 0.571 0.610 0.570 0.590 502,853 -
Summary
Current 2 Weeks
(06 Jan 2020 to 17 Jan 2020)
0.618 0.700 0.571 0.628 2,607,634 -
Previous 2 Weeks
(19 Dec 2019 to 03 Jan 2020)
0.582 0.700 0.571 0.631 2,431,572 -
4 Weeks from
(20 Nov 2019 to 18 Dec 2019)
0.570 0.700 0.560 0.592 8,297,420 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.